{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:38:30Z","timestamp":1791661110434,"version":"4.3.4"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-021-00781-1","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T19:05:35Z","timestamp":1642187135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["A review of prognostic and predictive biomarkers in breast cancer"],"prefix":"10.1007","author":[{"given":"Elaheh","family":"Tarighati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Keivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-0758","authenticated-orcid":false,"given":"Hojjat","family":"Mahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"6","key":"781_CR1","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.1016\/j.clbc.2018.07.020","volume":"18","author":"OS Ali","year":"2018","unstructured":"Ali OS, Shabayek MI, Seleem MM, Abdelaziz HG, Makhlouf DO. MicroRNAs 182 and 375 sera expression as prognostic biochemical markers in breast cancer. Clin Breast Cancer. 2018;18(6):e1373\u20139.","journal-title":"Clin Breast Cancer"},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145\u201364.","journal-title":"CA Cancer J Clin"},{"key":"781_CR3","volume-title":"Breast Cancer Facts & Figures 2019\u20132020","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc.; 2019."},{"issue":"S8","key":"781_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/cncr.23844","volume":"113","author":"BO Anderson","year":"2008","unstructured":"Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: Overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008;113(S8):2221\u201343.","journal-title":"Cancer"},{"issue":"Pt 1","key":"781_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcancer.2017.08.010","volume":"52","author":"A Nicolini","year":"2018","unstructured":"Nicolini A, Ferrari P, Duffy MJ,. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56\u201373.","journal-title":"Semin Cancer Biol."},{"issue":"9","key":"781_CR6","doi-asserted-by":"publisher","first-page":"15378","DOI":"10.1002\/jcb.28805","volume":"120","author":"Y Yao","year":"2019","unstructured":"Yao Y, Liu R, Gao C, et al. Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co-expression network. J Cell Biochem. 2019;120(9):15378\u201388.","journal-title":"J Cell Biochem"},{"key":"781_CR7","volume-title":"Biomarker\u2014Indicatorof Abnormal Physiological Process","author":"S Bertozzi","year":"2018","unstructured":"Bertozzi S, Londero AP, Seriau L, Di Vora R, Cedolini C, Mariuzzi L. Biomarkers in Breast Cancer. In: Begum G, editor. Biomarker\u2014Indicator of Abnormal Physiological Process. London: IntechOpen; 2018."},{"issue":"6","key":"781_CR8","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1002\/jcp.27716","volume":"234","author":"M Khordadmehr","year":"2019","unstructured":"Khordadmehr M, Shahbazi R, Ezzati H, Jigari-Asl F, Sadreddini S, Baradaran B. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J Cell Physiol. 2019;234(6):8316\u201326.","journal-title":"J Cell Physiol"},{"key":"781_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2016.11.012","volume":"172","author":"FJ Nassar","year":"2017","unstructured":"Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34\u201349.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"781_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2231-4040.72251","volume":"1","author":"GN Sharma","year":"2010","unstructured":"Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109.","journal-title":"J Adv Pharm Technol Res"},{"issue":"6","key":"781_CR11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc09-1791","volume":"33","author":"M Bodmer","year":"2010","unstructured":"Bodmer M, Meier C, Kr\u00e4henb\u00fchl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33(6):1304\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"781_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1373\/clinchem.2016.261834","volume":"63","author":"K Page","year":"2017","unstructured":"Page K, Guttery DS, Fernandez-Garcia D, et al. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clin Chem. 2017;63(2):532\u201341.","journal-title":"Clin Chem"},{"issue":"1","key":"781_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.","journal-title":"Biol Res"},{"issue":"Suppl 1","key":"781_CR14","doi-asserted-by":"publisher","first-page":"53S","DOI":"10.2967\/jnumed.115.157909","volume":"57","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W. Molecular imaging of biomarkers in breast cancer. J Nucl Med. 2016;57(Suppl 1):53S.","journal-title":"J Nucl Med"},{"key":"781_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/164_2015_24","volume-title":"Impact of biomarkers on personalized medicine. New approaches to drug discovery","author":"P Carrigan","year":"2015","unstructured":"Carrigan P, Krahn T. Impact of biomarkers on personalized medicine. New approaches to drug discovery. Berlin: Springer; 2015. p. 285\u2013311."},{"issue":"3","key":"781_CR16","first-page":"256","volume":"4","author":"N Goossens","year":"2015","unstructured":"Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4(3):256.","journal-title":"Transl Cancer Res"},{"issue":"2","key":"781_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","volume":"6","author":"NL Henry","year":"2012","unstructured":"Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140\u20136.","journal-title":"Mol Oncol"},{"issue":"27","key":"781_CR18","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"781_CR19","first-page":"157","volume":"11","author":"M Porika","year":"2010","unstructured":"Porika M, Malotu N, Veldandi UK, Yadala N, Abbagani S. Evaluation of tumor markers in southern Indian breast cancer patients. Asian Pac J Cancer Prev. 2010;11(1):157\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"781_CR20","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","volume":"32","author":"S Loibl","year":"2014","unstructured":"Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32:3212\u201320.","journal-title":"J Clin Oncol"},{"key":"781_CR21","doi-asserted-by":"crossref","unstructured":"Krop I, Johnston S, Mayer IA. The FERGI phase II study of the PI3 K inhibitor pictilisib (GDC-0941) plus fulvestrant vs. fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)- resistant advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2014; Abstract No. S2\u201302.","DOI":"10.1158\/1538-7445.SABCS14-S2-02"},{"issue":"1","key":"781_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0034-1396215","volume":"75","author":"PA Fasching","year":"2015","unstructured":"Fasching PA, Brucker SY, Fehm TN, et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network. Geburtsh Frauenheilk. 2015;75(1):41\u201350.","journal-title":"Geburtsh Frauenheilk"},{"issue":"2","key":"781_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wsbm.109","volume":"3","author":"W Zwart","year":"2011","unstructured":"Zwart W, Theodorou V, Carroll JS. Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med. 2011;3(2):216\u201330.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"781_CR24","doi-asserted-by":"publisher","first-page":"812540","DOI":"10.4061\/2011\/812540","volume":"2011","author":"R Kumar","year":"2011","unstructured":"Kumar R, Zakharov MN, Khan SH, et al. The dynamic structure of the estrogen receptor. J Amino Acids. 2011;2011:812540.","journal-title":"J Amino Acids."},{"issue":"4","key":"781_CR25","doi-asserted-by":"publisher","first-page":"R245","DOI":"10.1677\/ERC-10-0136","volume":"17","author":"MT Weigel","year":"2010","unstructured":"Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245\u201362.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"781_CR26","doi-asserted-by":"publisher","first-page":"e39432","DOI":"10.1371\/journal.pone.0039432","volume":"7","author":"C Jin","year":"2012","unstructured":"Jin C, Rajabi H, Pitroda S, Li A, et al. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS ONE. 2012;7(7):e39432.","journal-title":"PLoS ONE"},{"issue":"1","key":"781_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2016.07.015","volume":"17","author":"AC Tecalco-Cruz","year":"2017","unstructured":"Tecalco-Cruz AC, Ram\u00edrez-Jarqu\u00edn JO. Mechanisms that increase stability of estrogen receptor alpha in breast cancer. Clin Breast Cancer. 2017;17(1):1\u201310.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"781_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1517\/14712598.2010.485185","volume":"10","author":"S Yuan","year":"2010","unstructured":"Yuan S, Shi C, Liu L, Han W. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther. 2010;10(7):1037\u201348.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"781_CR29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00432-010-0787-x","volume":"136","author":"S Yuan","year":"2010","unstructured":"Yuan S, Shi C, Ling R, Wang T, Wang H, Han W. Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol. 2010;136(9):1359\u201367.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"781_CR30","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1016\/j.bmcl.2014.10.087","volume":"24","author":"X Li","year":"2014","unstructured":"Li X, Li L, Zhou Q, et al. Synthesis of the novel elemonic acid derivatives as Pin1 inhibitors. Bioorg Med Chem Lett. 2014;24(24):5612\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"781_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ptr.4986","volume":"28","author":"JH Kim","year":"2014","unstructured":"Kim JH, Jung JH, Kim SH, Jeong SJ. Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1\/p53 association. Phytother Res. 2014;28(2):238\u201344.","journal-title":"Phytother Res"},{"issue":"5","key":"781_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nm.3839","volume":"21","author":"S Wei","year":"2015","unstructured":"Wei S, Kozono S, Kats L, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21(5):457\u201366.","journal-title":"Nat Med"},{"issue":"4","key":"781_CR33","doi-asserted-by":"publisher","first-page":"e60383","DOI":"10.1371\/journal.pone.0060383","volume":"8","author":"HM Kim","year":"2013","unstructured":"Kim HM, Kim C-S, Lee J-H, et al. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS ONE. 2013;8(4):e60383.","journal-title":"PLoS ONE"},{"issue":"1","key":"781_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1096\/fj.03-0038com","volume":"18","author":"AM Fowler","year":"2004","unstructured":"Fowler AM, Solodin N, Preisler-Mashek MT, Zhang P, Lee AV, Alarid ET. Increases in estrogen receptor-\u03b1 concentration in breast cancer cells promote serine 118\/104\/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J. 2004;18(1):81\u201393.","journal-title":"FASEB J"},{"issue":"2","key":"781_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1210\/me.2005-0288","volume":"20","author":"AM Fowler","year":"2006","unstructured":"Fowler AM, Solodin NM, Valley CC, Alarid ET. Altered target gene regulation controlled by estrogen receptor-\u03b1 concentration. Mol Endocrinol. 2006;20(2):291\u2013301.","journal-title":"Mol Endocrinol"},{"issue":"5","key":"781_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/092986713804999303","volume":"20","author":"F Lumachi","year":"2013","unstructured":"Lumachi F, Brunello A, Maruzzo M, Basso U, M.M Basso S,. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596\u2013604.","journal-title":"Curr Med Chem"},{"issue":"2","key":"781_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tice.2016.02.002","volume":"48","author":"AM Kabel","year":"2016","unstructured":"Kabel AM, Elkhoely AA. Ameliorative potential of fluoxetine\/raloxifene combination on experimentally induced breast cancer. Tissue Cell. 2016;48(2):89\u201395.","journal-title":"Tissue Cell"},{"issue":"8","key":"781_CR38","doi-asserted-by":"publisher","first-page":"e2909","DOI":"10.1097\/MD.0000000000002909","volume":"95","author":"HH Han","year":"2016","unstructured":"Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH. Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients. Medicine. 2016;95(8):e2909.","journal-title":"Medicine."},{"issue":"11","key":"781_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.neo.2016.08.007","volume":"18","author":"N Beije","year":"2016","unstructured":"Beije N, Onstenk W, Kraan J, et al. Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. Neoplasia. 2016;18(11):647\u201353.","journal-title":"Neoplasia"},{"issue":"8","key":"781_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/PAI.0000000000000337","volume":"25","author":"HE Gulbahce","year":"2017","unstructured":"Gulbahce HE, Blair CK, Sweeney C, Salama ME. Quantification of estrogen receptor expression in normal breast tissue in postmenopausal women with breast cancer and association with tumor subtypes. Appl Immunohistochem Mol Morphol. 2017;25(8):548\u201352.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"781_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjbcancer.2016.32","volume":"2","author":"H Oh","year":"2016","unstructured":"Oh H, Eliassen AH, Wang M, et al. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2(1):1\u20133.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"781_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-0146-2","volume":"6","author":"D Caruana","year":"2020","unstructured":"Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. NPJ Breast Cancer. 2020;6(1):1\u20136.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"781_CR43","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1530\/EJE-16-0124","volume":"175","author":"J Carroll","year":"2016","unstructured":"Carroll J. EJE PRIZE 2016: mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 2016;175(1):R41\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"781_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","volume":"15","author":"SY Bae","year":"2015","unstructured":"Bae SY, Kim S, Lee JH, et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15(1):138.","journal-title":"BMC Cancer"},{"issue":"5","key":"781_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"781_CR46","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor\u2013positive breast cancer. Clin Cancer Res. 2014;20(7):1757\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"781_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-018-0093-3","volume":"4","author":"S Kumar","year":"2018","unstructured":"Kumar S, Lindsay D, Chen QB, et al. Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer. 2018;4(1):1\u20135.","journal-title":"NPJ Breast Cancer"},{"issue":"313","key":"781_CR48","doi-asserted-by":"publisher","first-page":"313ra182\u2013313ra1","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182-313ra182.","journal-title":"Sci Transl Med"},{"issue":"10","key":"781_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"781_CR50","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1158\/1078-0432.CCR-13-2437","volume":"20","author":"AY Helena","year":"2014","unstructured":"Helena AY, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2014;20(23):5898\u2013907.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"781_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1535-7163.MCT-13-0518","volume":"13","author":"SW Brady","year":"2014","unstructured":"Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110\u03b1 signaling confers acquired lapatinib resistance that can be effectively reversed by a p110\u03b1-selective PI3K inhibitor. Mol Cancer Ther. 2014;13(1):60\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"781_CR52","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bcp.2011.12.025","volume":"83","author":"SA Rosenzweig","year":"2012","unstructured":"Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83(8):1041\u20138.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"781_CR53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737159.2019.1631799","volume":"19","author":"M Carausu","year":"2019","unstructured":"Carausu M, Bidard F-C, Callens C, et al. ESR1 mutations: a new biomarker in breast cancer. Expert Rev Mol Diagn. 2019;19(7):599\u2013611.","journal-title":"Expert Rev Mol Diagn"},{"issue":"12","key":"781_CR54","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439.","journal-title":"Nat Genet"},{"issue":"12","key":"781_CR55","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/cancers11121894","volume":"11","author":"I De Santo","year":"2019","unstructured":"De Santo I, McCartney A, Migliaccio I, Di Leo A, Malorni L. The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy. Cancers. 2019;11(12):1894.","journal-title":"Cancers"},{"issue":"1","key":"781_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0808-y","volume":"17","author":"T Takeshita","year":"2018","unstructured":"Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Mol Cancer. 2018;17(1):1\u20136.","journal-title":"Mol Cancer"},{"issue":"11","key":"781_CR57","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O'Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403.","journal-title":"Cancer Discov"},{"key":"781_CR58","doi-asserted-by":"publisher","first-page":"1947215","DOI":"10.1155\/2019\/1947215","volume":"2019","author":"T Reinert","year":"2019","unstructured":"Reinert T, Coelho GP, Mandelli J, et al. Association of ESR1 mutations and visceral metastasis in patients with estrogen receptor-positive advanced breast cancer from Brazil. J Oncol. 2019;2019:1947215.","journal-title":"J Oncol."},{"issue":"2","key":"781_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","volume":"17","author":"DP English","year":"2013","unstructured":"English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85\u201399.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"781_CR60","first-page":"4","volume":"2","author":"T Ishikawa","year":"2014","unstructured":"Ishikawa T, Ichikawa Y, Shimizu D, et al. The role of HER-2 in Breast Cancer. J Surg Sci. 2014;2(1):4.","journal-title":"J Surg Sci"},{"issue":"3","key":"781_CR61","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/bjc.1991.103","volume":"63","author":"J Winstanley","year":"1991","unstructured":"Winstanley J, Cooke T, Murray G, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63(3):447.","journal-title":"Br J Cancer"},{"issue":"2","key":"781_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100\u20137.","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"781_CR63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1309\/C6X54HRB580EP2NQ","volume":"128","author":"W Cao","year":"2007","unstructured":"Cao W, Zhang B, Liu Y, et al. High-level SLP-2 expression and HER-2\/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol. 2007;128(3):430\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"781_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-016-4000-z","volume":"160","author":"N Reix","year":"2016","unstructured":"Reix N, Malina C, Chenard M-P, et al. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Breast Cancer Res Treat. 2016;160(2):249\u201359.","journal-title":"Breast Cancer Res Treat"},{"key":"781_CR65","doi-asserted-by":"publisher","first-page":"102064","DOI":"10.1016\/j.ctrv.2020.102064","volume":"88","author":"MV Dieci","year":"2020","unstructured":"Dieci MV, Miglietta F, Griguolo G, Guarneri V. Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors. Cancer Treat Rev. 2020;88:102064.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"781_CR66","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jnci\/djh131","volume":"96","author":"MD Pegram","year":"2004","unstructured":"Pegram MD, Konecny GE, O\u2019Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst Monogr. 2004;96(10):739\u201349.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"781_CR67","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"M Duffy","year":"2017","unstructured":"Duffy M, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284\u201398.","journal-title":"Eur J Cancer"},{"key":"781_CR68","doi-asserted-by":"publisher","first-page":"109647","DOI":"10.1016\/j.biopha.2019.109647","volume":"121","author":"J-R Wu","year":"2020","unstructured":"Wu J-R, Zhao Y, Zhou X-P, Qin X. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Biomed Pharmacother. 2020;121:109647.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"781_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1586\/eem.11.25","volume":"6","author":"AR Daniel","year":"2011","unstructured":"Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011;6(3):359\u201369.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"7560","key":"781_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature. 2015;523(7560):313\u20137.","journal-title":"Nature"},{"issue":"1","key":"781_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nrc.2016.116","volume":"17","author":"JS Carroll","year":"2017","unstructured":"Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD. Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer. 2017;17(1):54\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"781_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","volume":"89","author":"RM Elledge","year":"2000","unstructured":"Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. Int J Cancer. 2000;89(2):111\u20137.","journal-title":"Int J Cancer"},{"issue":"3","key":"781_CR73","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10549-012-1990-z","volume":"134","author":"X Chen","year":"2012","unstructured":"Chen X, Yuan Y, Gu Z, Shen K. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;134(3):957\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"38","key":"781_CR74","doi-asserted-by":"publisher","first-page":"63963","DOI":"10.18632\/oncotarget.19246","volume":"8","author":"C Fang","year":"2017","unstructured":"Fang C, Cao Y, Liu X, Zeng X-T, Li Y. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget. 2017;8(38):63963.","journal-title":"Oncotarget"},{"issue":"7","key":"781_CR75","doi-asserted-by":"publisher","first-page":"e0133830","DOI":"10.1371\/journal.pone.0133830","volume":"10","author":"Y Shao","year":"2015","unstructured":"Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15\u20133 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE. 2015;10(7):e0133830.","journal-title":"PLoS ONE"},{"issue":"3","key":"781_CR76","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122(3):467\u201381.","journal-title":"J Exp Med"},{"issue":"1","key":"781_CR77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2013.11.003","volume":"23","author":"S-g Wu","year":"2014","unstructured":"Wu S-g, He Z-y, Zhou J, et al. Serum levels of CEA and CA15\u20133 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88\u201393.","journal-title":"Breast"},{"issue":"23\u201324","key":"781_CR78","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","volume":"411","author":"MJ Duffy","year":"2010","unstructured":"Duffy MJ, Evoy D, McDermott EW. CA 15\u20133: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411(23\u201324):1869\u201374.","journal-title":"Clin Chim Acta"},{"key":"781_CR79","doi-asserted-by":"crossref","unstructured":"Li J, Liu L, Feng Z, et al. Tumor markers CA15\u20133, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020:1\u201310.","DOI":"10.1007\/s12282-020-01058-3"},{"issue":"6","key":"781_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000089260","volume":"26","author":"R Molina","year":"2005","unstructured":"Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer\u2013European Group on Tumor Markers recommendations. Tumor Biol. 2005;26(6):281\u201393.","journal-title":"Tumor Biol"},{"issue":"1","key":"781_CR81","first-page":"241","volume":"35","author":"P Mari\u0107","year":"2011","unstructured":"Mari\u0107 P, Ozreti\u0107 P, Levanat S, Ore\u0161kovi\u0107 S, Antunac K, Beketi\u0107-Ore\u0161kovi\u0107 L. Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol. 2011;35(1):241\u20137.","journal-title":"Coll Antropol"},{"issue":"3","key":"781_CR82","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1373\/clinchem.2003.025288","volume":"50","author":"MJ Duffy","year":"2004","unstructured":"Duffy MJ, Duggan C, Keane R, et al. High preoperative CA 15\u20133 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50(3):559\u201363.","journal-title":"Clin Chem"},{"issue":"2","key":"781_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1020514925143","volume":"76","author":"EJ Kumpulainen","year":"2002","unstructured":"Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002;76(2):95\u2013102.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"781_CR84","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol"},{"issue":"4","key":"781_CR85","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/annonc\/mdm538","volume":"19","author":"B-W Park","year":"2008","unstructured":"Park B-W, Oh J-W, Kim J-H, et al. Preoperative CA 15\u20133 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19(4):675\u201381.","journal-title":"Ann Oncol"},{"issue":"7","key":"781_CR86","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1373\/clinchem.2009.135566","volume":"56","author":"R Molina","year":"2010","unstructured":"Molina R, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem. 2010;56(7):1148\u201357.","journal-title":"Clin Chem"},{"issue":"3","key":"781_CR87","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-013-2695-7","volume":"141","author":"JS Lee","year":"2013","unstructured":"Lee JS, Park S, Park JM, Cho JH, Kim SI, Park B-W. Elevated levels of serum tumor markers CA 15\u20133 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat. 2013;141(3):477\u201384.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"781_CR88","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-016-4014-6","volume":"160","author":"JS Lee","year":"2016","unstructured":"Lee JS, Magbanua MJM, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016;160(3):411\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"781_CR89","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483.","journal-title":"J Clin Oncol"},{"issue":"4","key":"781_CR90","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12609-013-0125-9","volume":"5","author":"F Le Du","year":"2013","unstructured":"Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast cancer biomarkers: utility in clinical practice. Curr Breast Cancer Rep. 2013;5(4):284\u201392.","journal-title":"Curr Breast Cancer Rep"},{"issue":"5","key":"781_CR91","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3816\/CBC.2010.n.052","volume":"10","author":"E Munzone","year":"2010","unstructured":"Munzone E, Nol\u00e9 F, Goldhirsch A, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010;10(5):392\u20137.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"781_CR92","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","volume":"134","author":"M Pestrin","year":"2012","unstructured":"Pestrin M, Bessi S, Puglisi F, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"781_CR93","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","volume":"16","author":"M Cristofanilli","year":"2010","unstructured":"Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904\u201314.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"781_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3180","volume":"14","author":"R Nadal","year":"2012","unstructured":"Nadal R, Fernandez A, Sanchez-Rovira P, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012;14(3):1\u201312.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"781_CR95","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","volume":"13","author":"NA Soliman","year":"2016","unstructured":"Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496.","journal-title":"Cancer Biol Med"},{"issue":"2","key":"781_CR96","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pathol.2016.11.006","volume":"49","author":"F Penault-Llorca","year":"2017","unstructured":"Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166\u201371.","journal-title":"Pathology"},{"issue":"52","key":"781_CR97","doi-asserted-by":"publisher","first-page":"85798","DOI":"10.18632\/oncotarget.12622","volume":"7","author":"X Feng","year":"2016","unstructured":"Feng X, Li H, Kornaga EN, et al. Low Ki67\/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer. Oncotarget. 2016;7(52):85798.","journal-title":"Oncotarget"},{"issue":"2","key":"781_CR98","doi-asserted-by":"publisher","first-page":"e0172324","DOI":"10.1371\/journal.pone.0172324","volume":"12","author":"Y Pan","year":"2017","unstructured":"Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS ONE. 2017;12(2):e0172324.","journal-title":"PLoS ONE"},{"issue":"10\u201313","key":"781_CR99","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0039-128X(03)00122-3","volume":"68","author":"RB Clarke","year":"2003","unstructured":"Clarke RB. Steroid receptors and proliferation in the human breast. Steroids. 2003;68(10\u201313):789\u201394.","journal-title":"Steroids"},{"issue":"1","key":"781_CR100","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/gme.0b013e318054e29a","volume":"15","author":"JA Harvey","year":"2008","unstructured":"Harvey JA, Santen RJ, Petroni GR, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause. 2008;15(1):67.","journal-title":"Menopause"},{"issue":"2","key":"781_CR101","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12253-008-9100-6","volume":"15","author":"C-j Zhou","year":"2009","unstructured":"Zhou C-j, Zhang Q-h, Zhang T-g, et al. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients. Pathol Oncol Res. 2009;15(2):153\u20138.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"781_CR102","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-015-3559-0","volume":"153","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477\u201391.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"781_CR103","doi-asserted-by":"publisher","first-page":"e0141332","DOI":"10.1371\/journal.pone.0141332","volume":"10","author":"P-J Li","year":"2015","unstructured":"Li P-J, Jin T, Luo D-H, et al. Effect of prolonged radiotherapy treatment time on survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. PLoS ONE. 2015;10(10):e0141332.","journal-title":"PLoS ONE"},{"issue":"1","key":"781_CR104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-006-9476-5","volume":"106","author":"CJ Fabian","year":"2007","unstructured":"Fabian CJ, Kimler BF, Zalles CM, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat. 2007;106(1):75\u201384.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"781_CR105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1471-2407-8-287","volume":"8","author":"Y Okumura","year":"2008","unstructured":"Okumura Y, Yamamoto Y, Zhang Z, et al. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer. 2008;8(1):287.","journal-title":"BMC Cancer"},{"issue":"12","key":"781_CR106","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(01)00165-4","volume":"37","author":"A Ringberg","year":"2001","unstructured":"Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fern\u00f6 M. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer. 2001;37(12):1514\u201322.","journal-title":"Eur J Cancer"},{"issue":"7","key":"781_CR107","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.7314\/APJCP.2013.14.7.4353","volume":"14","author":"S Haroon","year":"2013","unstructured":"Haroon S, Hashmi AA, Khurshid A, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev. 2013;14(7):4353\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"781_CR108","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3892\/etm.2010.133","volume":"1","author":"R Nishimura","year":"2010","unstructured":"Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5):747\u201354.","journal-title":"Exp Ther Med"},{"issue":"2","key":"781_CR109","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jgeb.2018.03.002","volume":"16","author":"HM Ragab","year":"2018","unstructured":"Ragab HM, Samy N, Afify M, Abd El Maksoud N, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J Genet Eng Biotechnol. 2018;16(2):479\u201384.","journal-title":"J Genet Eng Biotechnol"},{"issue":"2","key":"781_CR110","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174\u201383.","journal-title":"Lancet Oncol"},{"issue":"18","key":"781_CR111","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1101\/gad.1446006","volume":"20","author":"J Eeckhoute","year":"2006","unstructured":"Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006;20(18):2513\u201326.","journal-title":"Genes Dev"},{"issue":"11","key":"781_CR112","doi-asserted-by":"publisher","first-page":"e0188068","DOI":"10.1371\/journal.pone.0188068","volume":"12","author":"AB Ortiz","year":"2017","unstructured":"Ortiz AB, Garcia D, Vicente Y, Palka M, Bellas C, Martin P. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS ONE. 2017;12(11):e0188068.","journal-title":"PLoS ONE"},{"issue":"15","key":"781_CR113","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.4161\/cc.25403","volume":"12","author":"R Lamb","year":"2013","unstructured":"Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G. Cell cycle regulators cyclin D1 and CDK4\/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 2013;12(15):2384\u201394.","journal-title":"Cell Cycle"},{"issue":"2","key":"781_CR114","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ijc.25034","volume":"127","author":"PG Roy","year":"2010","unstructured":"Roy PG, Pratt N, Purdie CA, et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer. 2010;127(2):355\u201360.","journal-title":"Int J Cancer"},{"issue":"10","key":"781_CR115","doi-asserted-by":"publisher","first-page":"16861","DOI":"10.1002\/jcp.28368","volume":"234","author":"M Khordadmehr","year":"2019","unstructured":"Khordadmehr M, Shahbazi R, Sadreddini S, Baradaran B. miR-193: a new weapon against cancer. J Cell Physiol. 2019;234(10):16861\u201372.","journal-title":"J Cell Physiol"},{"issue":"16","key":"781_CR116","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1158\/1078-0432.CCR-12-3401","volume":"19","author":"M Chan","year":"2013","unstructured":"Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19(16):4477\u201387.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"781_CR117","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1200\/JCO.2010.29.8901","volume":"28","author":"HM Heneghan","year":"2010","unstructured":"Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol. 2010;28(29):e573\u20134.","journal-title":"J Clin Oncol"},{"issue":"5","key":"781_CR118","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.molonc.2014.03.002","volume":"8","author":"AR Kodahl","year":"2014","unstructured":"Kodahl AR, Lyng MB, Binder H, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol. 2014;8(5):874\u201383.","journal-title":"Mol Oncol"},{"issue":"3","key":"781_CR119","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cas.12880","volume":"107","author":"A Shimomura","year":"2016","unstructured":"Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107(3):326\u201334.","journal-title":"Cancer Sci"},{"issue":"5\u20136","key":"781_CR120","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/genesandcancer.66","volume":"6","author":"HA Hagrass","year":"2015","unstructured":"Hagrass HA, Sharaf S, Pasha HF, Tantawy EA, Mohamed RH, Kassem R. Circulating microRNAs-a new horizon in molecular diagnosis of breast cancer. Genes Cancer. 2015;6(5\u20136):281.","journal-title":"Genes Cancer"},{"issue":"11","key":"781_CR121","doi-asserted-by":"publisher","first-page":"19199","DOI":"10.1002\/jcp.28656","volume":"234","author":"Z Bahmanpour","year":"2019","unstructured":"Bahmanpour Z, Sheervalilou R, Choupani J, Shekari Khaniani M, Montazeri V, Mansoori DS. A new insight on serum microRNA expression as novel biomarkers in breast cancer patients. J Cell Physiol. 2019;234(11):19199\u2013211.","journal-title":"J Cell Physiol"},{"issue":"1","key":"781_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-51","volume":"12","author":"Z-s Wu","year":"2012","unstructured":"Wu Z-s, Wang C-q, Xiang R, et al. Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer. 2012;12(1):1\u201310.","journal-title":"BMC Cancer"},{"issue":"1","key":"781_CR123","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1479-5876-10-42","volume":"10","author":"X Wu","year":"2012","unstructured":"Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10(1):42.","journal-title":"J Transl Med"},{"issue":"1","key":"781_CR124","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jss.2014.12.035","volume":"195","author":"R Zheng","year":"2015","unstructured":"Zheng R, Pan L, Gao J, et al. Prognostic value of miR-106b expression in breast cancer patients. J Surg Res. 2015;195(1):158\u201365.","journal-title":"J Surg Res"},{"issue":"4","key":"781_CR125","doi-asserted-by":"publisher","first-page":"e34210","DOI":"10.1371\/journal.pone.0034210","volume":"7","author":"H Wang","year":"2012","unstructured":"Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE. 2012;7(4):e34210.","journal-title":"PLoS ONE"},{"key":"781_CR126","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"781_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13058-020-01303-9","volume":"22","author":"H Guo","year":"2020","unstructured":"Guo H, Ding Q, Gong Y, et al. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020;22:69.","journal-title":"Breast Cancer Res"},{"key":"781_CR128","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","volume":"146","author":"S Muenst","year":"2014","unstructured":"Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146:15\u201324.","journal-title":"Breast Cancer Res Treat"},{"key":"781_CR129","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.humpath.2015.09.006","volume":"47","author":"MZ Baptista","year":"2016","unstructured":"Baptista MZ, Sarian LO, Derchain SFM, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47:78\u201384.","journal-title":"Hum Pathol"},{"key":"781_CR130","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.5583","volume":"6","author":"T Qin","year":"2015","unstructured":"Qin T, Zeng Y, Qin G, et al. High PD-L1expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6:33972\u201381.","journal-title":"Oncotarget"},{"key":"781_CR131","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.18632\/oncotarget.3216","volume":"6","author":"R Sabatier","year":"2014","unstructured":"Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2014;6:5449\u201364.","journal-title":"Oncotarget"},{"key":"781_CR132","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumaband nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"781_CR133","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326\u201332.","journal-title":"Cancer Immunol Res"},{"key":"781_CR134","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, DeMaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by anInternational TILs Working Group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"781_CR135","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","volume":"29","author":"C Denkert","year":"2016","unstructured":"Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29:1155\u201364.","journal-title":"Mod Pathol"},{"key":"781_CR136","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40\u201350.","journal-title":"Lancet Oncol"},{"key":"781_CR137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13058-020-01285-8","volume":"22","author":"SK Skriver","year":"2020","unstructured":"Skriver SK, Jensen MB, Knoop AS, Ejlertsen B, Laenkholm AV. Tumour-infiltrating lymphocytes and response toneoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: Analysis from a nationwide phase II DBCGtrial. Breast Cancer Res. 2020;22:46.","journal-title":"Breast Cancer Res"},{"issue":"33","key":"781_CR138","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287\u2013312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"781_CR139","first-page":"487","volume":"12","author":"S Zervoudis","year":"2007","unstructured":"Zervoudis S, Peitsidis P, Iatrakis G, et al. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON. 2007;12(4):487.","journal-title":"J BUON"},{"issue":"27","key":"781_CR140","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048.","journal-title":"J Clin Oncol"},{"key":"781_CR141","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/S0959-8049(02)80604-9","volume":"38","author":"AD van den Abbeele","year":"2002","unstructured":"van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38:S60\u20135.","journal-title":"Eur J Cancer"},{"issue":"12","key":"781_CR142","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987\u201392.","journal-title":"J Clin Oncol"},{"issue":"6","key":"781_CR143","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","volume":"30","author":"N Niikura","year":"2012","unstructured":"Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593.","journal-title":"J Clin Oncol"},{"issue":"5","key":"781_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2645","volume":"12","author":"LD Hoefnagel","year":"2010","unstructured":"Hoefnagel LD, van de Vijver MJ, van Slooten H-J, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12(5):1\u20139.","journal-title":"Breast Cancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00781-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:59:53Z","timestamp":1726466393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00781-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":144,"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00781-1","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}